Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.53 +0.15 (+1.09%)
Streaming Delayed Price Updated: 9:50 AM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
News headline image
Why Is Intellia (NTLA) Stock Up 5% Today? ↗
NTLA stock is trending on social media and is up over 5%. The drugmaker reported new, positive results from its gene-edited treatment. 
Via InvestorPlace
News headline image
Intellia Therapeutics Surges As CRISPR Gene-Editing Drug Potentially Cures Swelling Disease ↗
The company is testing a treatment for hereditary angioedemia, a potentially fatal swelling disorder. 
Via Investor's Business Daily
News headline image
Why Intellia Therapeutics Stock Is Rising Monday ↗
Intellia Therapeutics Inc (NASDAQ: NTLA) shares are trading higher Monday after the clinical-stage genome editing company announced data for its treatment for people living with hereditary angioedema... 
Via Benzinga
News headline image
Chinook Therapeutics, Oracle And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. Chinook Therapeutics, Inc. (NASDAQ: KDNY) shares jumped 66.8% to $40.01 in... 
Via Benzinga
News headline image
Can This Gene-Editing Stock Deliver 10X Returns? ↗
Buying shares of Intellia Therapeutics might be a smart move. 
Via The Motley Fool
News headline image
12 Analysts Have This to Say About Intellia Therapeutics ↗
 
Via Benzinga
News headline image
Intellia Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Intellia Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Where Intellia Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Ratings for Intellia Therapeutics ↗
 
Via Benzinga
News headline image
Wall Street Says These 2 Stocks May Double. Should You Buy Them? ↗
Both of these stocks have declined over the past year. 
Via The Motley Fool
News headline image
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You? ↗
The Ark Invest CEO is betting on rebounds for these beaten-down stocks. 
Via The Motley Fool
News headline image
Why Intellia Therapeutics Shares Are Surging Today ↗
Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares are up Thursday as its Q1 results surpassed estimates. The company looks forward to sharing new interim data from NTLA-2001 and NTLA-2002... 
Via Benzinga
News headline image
The 3 Most Promising Gene Editing Stocks to Buy in 2023 ↗
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in. 
Via InvestorPlace
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The popular growth investor has stumbled after a hot start to 2023, but Wood keeps adding to some of her favorite positions. 
Via The Motley Fool
News headline image
3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat ↗
Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat. 
Via InvestorPlace
News headline image
3 High-Growth Biotech Stocks Poised for Success in 2023 ↗
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity 
Via InvestorPlace
News headline image
2 Monster Growth Stocks That Can Double in Value, According to Wall Street ↗
These stocks have some promising growth opportunities, but they also come with a fair amount of risk. 
Via The Motley Fool
News headline image
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today? ↗
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023 ↗
 
Via Benzinga
News headline image
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global ↗
 
Via Benzinga
News headline image
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
News headline image
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗
 
Via Benzinga
News headline image
3 Beaten-Down Stocks That Could Soar This Year ↗
These stocks could enjoy big rebounds in 2023. 
Via The Motley Fool
News headline image
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money ↗
There are no guarantees that any stock will generate huge returns. But the odds look pretty good for these three growth stocks. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 ↗
 
Via Benzinga
News headline image
2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash ↗
Are these stocks still good buys today? 
Via The Motley Fool
News headline image
7 Cathie Wood Stocks for Your March Buy List ↗
These top Cathie Wood stocks are just now attempting to pivot higher after a miserable outing for much of 2022. 
Via InvestorPlace
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.